Compare IMC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMC | ACHV |
|---|---|---|
| Founded | 2025 | N/A |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.3M | 726.5M |
| IPO Year | 2026 | 2018 |
| Metric | IMC | ACHV |
|---|---|---|
| Price | $10.72 | $6.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $14.15 |
| AVG Volume (30 Days) | 106.8K | ★ 1.3M |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.80 | $2.62 |
| 52 Week High | $12.00 | $8.64 |
| Indicator | IMC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 44.06 |
| Support Level | $6.23 | $5.96 |
| Resistance Level | $11.84 | $7.30 |
| Average True Range (ATR) | 1.16 | 0.38 |
| MACD | 0.48 | 0.04 |
| Stochastic Oscillator | 73.33 | 43.93 |
IMC Rare Earths Ltd is a mineral exploration and development company engaged in the exploration, evaluation and development of minerals and metals in Brazil. Its main REE project is the Itarantim Project located in the States of Bahia and Minas Gerais, Brazil.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.